HIV's effect on white blood cells questioned by new research

Scientists have refuted a longstanding theory of how HIV slowly depletes the body’s capacity to fight infection, in new research published today.

The researchers were looking at T helper cells, a class of white blood cells which recognise infection and co-ordinate the body’s immune defences. They are attacked by HIV, and their numbers gradually decline in HIV positive patients. It has long been a major puzzle why this process of depletion is so slow, often taking 10 years or more.

One popular theory has been the “runaway” hypothesis, which says that T cells infected by HIV produce more HIV virus particles, which activate more T cells, that in turn become infected, leading to an uncontrolled cycle of T cell activation, infection, HIV production and cell destruction.

However, today’s new study in PLoS Medicine shows that this theory cannot explain the very slow pace of depletion that occurs in HIV infection. The research team used a mathematical model of the processes by which T cells are produced and eliminated to show that if the runaway theory was correct, then T helper cell numbers would fall to very low levels over a number of months, not years.

One of the paper’s authors is Jaroslav Stark, Professor of Mathematics at Imperial College London, and Director of the Centre of Integrative Systems Biology at Imperial. He said: “Scientists have never had a full understanding of the processes by which T helper cells are depleted in HIV, and therefore they’ve been unable to fully explain why HIV destroys the body’s supply of these cells at such a slow rate. Our new interdisciplinary research has thrown serious doubt on one popular theory of how HIV affects these cells, and means that further studies are required to understand the mechanism behind HIV’s distinctive slow process of cellular destruction.”

The research team think that one possible explanation could be that the virus slowly adapts itself over the course of the infection, but they stress that further analysis is needed to verify this alternative theory.

Professor Stark adds: “If the specific process by which HIV depletes this kind of white blood cells can be identified, it could pave the way for potential new approaches to treatment.”

Source: Imperial College London

Related stories:

Discovery of virus in lemur could shed light on AIDS
The genome of a squirrel-sized, saucer-eyed lemur from Madagascar may help scientists understand how HIV-like viruses coevolved with primates, according to new research from the Stanford University School of Medicine. The discovery, to be published online on Dec. 1 in the Proceedings of the National Academy of Sciences, could provide insight into why non-human primates don't get AIDS and lead to treatments for humans.
Selenium may slow march of AIDS
Increasing the production of naturally occurring proteins that contain selenium in human blood cells slows down multiplication of the AIDS virus, according to biochemists.
Researchers develop new strategy for broad spectrum anti-viral drugs
Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents.
Stopping germs from ganging up on humans
Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson.
Why HIV treatment makes people so susceptible to heart disease and diabetes
Clinicians have known for some time that people treated for HIV also become much more susceptible to diabetes and heart disease. A study by scientists at Sydney's Garvan Institute of Medical Research has now shown some of the reasons why – enabling better patient management and monitoring.
Novel regulatory step during HIV replication
A previously unknown regulatory step during human immunodeficiency (HIV) replication provides a potentially valuable new target for HIV/AIDS therapy, report researchers at the Salk Institute for Biological Studies and the University of Wisconsin, Madison.
Results of landmark study of HIV vaccine published in the Lancet
Results from the Step study, a test-of-concept efficacy study of a Merck & Co., Inc. HIV vaccine candidate, were published online today in two papers in The Lancet. These analyses of the Step study are being conducted, presented and published to inform the continued search for an effective HIV vaccine.
Recovering antibodies from 1918 flu pandemic survivors
(PhysOrg.com) -- Ninety years after the sweeping destruction of the 1918 flu pandemic, researchers at the Monroe Carell Jr. Children's Hospital at Vanderbilt have recovered antibodies to the virus — from elderly survivors of the original outbreak.

News discussion:

Medicine & Health news